Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Broadcom
AVGO
|
+$472M |
| 2 |
Advanced Micro Devices
AMD
|
+$296M |
| 3 |
Apple
AAPL
|
+$275M |
| 4 |
Qualcomm
QCOM
|
+$218M |
| 5 |
NVIDIA
NVDA
|
+$187M |
Top Sells
| 1 |
Amazon
AMZN
|
+$536M |
| 2 |
Uber
UBER
|
+$438M |
| 3 |
Chevron
CVX
|
+$280M |
| 4 |
Meta Platforms (Facebook)
META
|
+$264M |
| 5 |
CrowdStrike
CRWD
|
+$242M |
Sector Composition
| 1 | Technology | 19.65% |
| 2 | Healthcare | 18.08% |
| 3 | Consumer Discretionary | 13.75% |
| 4 | Industrials | 8.66% |
| 5 | Financials | 7.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3026
Carisma Therapeutics
CARM
$15.8M
| $212K | ﹤0.01% |
139,360
-86,635
| -38% | -$132K |
|
3027
Lipocine
LPCN
$15.9M
| $212K | ﹤0.01% |
25,697
+4,600
| +22% | +$37.9K |
|
3028
IO Biotech
IOBT
$126M
| $212K | ﹤0.01% |
180,800
+13,600
| +8% | +$15.9K |
|
3029
Marker Therapeutics
MRKR
$12.6M
| $211K | ﹤0.01% |
38,850
+1,600
| +4% | +$8.69K |
|
3030
HF Foods Group
HFFG
$183M
| $211K | ﹤0.01% |
70,300
+5,000
| +8% | +$15K |
|
|
RGLS
3031
DELISTED
Regulus Therapeutics
RGLS
| $211K | ﹤0.01% |
118,100
+42,600
| +56% | +$76K |
|
3032
First Trust Capital Strength ETF
FTCS
$8.53B
| $210K | ﹤0.01% |
2,500
-22,000
| -90% | -$1.85M |
|
3033
Mesa Laboratories
MLAB
$347M
| $208K | ﹤0.01% |
2,400
-13,700
| -85% | -$1.19M |
|
|
HSAI
3034
Hesai Group
HSAI
$3.74B
| $208K | ﹤0.01% |
49,700
+15,200
| +44% | +$63.7K |
|
3035
Equillium
EQ
$118M
| $208K | ﹤0.01% |
300,400
+91,200
| +44% | +$63.2K |
|
3036
Bolt Biotherapeutics
BOLT
$10.1M
| $208K | ﹤0.01% |
13,837
-12,045
| -47% | -$181K |
|
3037
German American Bancorp
GABC
$1.54B
| $207K | ﹤0.01% |
+5,849
| New | +$207K |
|
3038
PEDEVCO
PED
$55M
| $206K | ﹤0.01% |
227,815
+9,311
| +4% | +$8.42K |
|
3039
CareCloud
CCLD
$160M
| $206K | ﹤0.01% |
107,200
+21,500
| +25% | +$41.3K |
|
|
DAO
3040
Youdao
DAO
$1.06B
| $205K | ﹤0.01% |
52,300
+3,300
| +7% | +$12.9K |
|
3041
First Trust RBA American Industrial Renaissance ETF
AIRR
$5.33B
| $205K | ﹤0.01% |
+3,000
| New | +$205K |
|
3042
Astria Therapeutics
ATXS
$442M
| $204K | ﹤0.01% |
22,461
-18,939
| -46% | -$172K |
|
|
CTHR
3043
DELISTED
Charles & Colvard Ltd
CTHR
| $204K | ﹤0.01% |
119,069
-19,568
| -14% | -$33.5K |
|
3044
ClearOne
CLRO
$8.2M
| $204K | ﹤0.01% |
20,877
-1,327
| -6% | -$12.9K |
|
|
SSY
3045
DELISTED
SunLink Health Systems
SSY
| $203K | ﹤0.01% |
253,478
-2,900
| -1% | -$2.32K |
|
3046
Priority Technology Holdings
PRTH
$610M
| $202K | ﹤0.01% |
+38,300
| New | +$202K |
|
3047
CEL-SCI Corp
CVM
$67.7M
| $202K | ﹤0.01% |
5,793
+1,333
| +30% | +$46.4K |
|
3048
Direxion Daily Energy Bear 2X Shares
ERY
$22.1M
| $202K | ﹤0.01% |
+8,800
| New | +$202K |
|
3049
SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
$14.5B
| $200K | ﹤0.01% |
3,900
-1,200
| -24% | -$61.6K |
|
3050
Globalstar
GSAT
$3.84B
| $198K | ﹤0.01% |
11,775
+1,346
| +13% | +$22.6K |
|